Boyce Sarah, President and CEO of Avidity Biosciences, Inc. ($RNAM), sold shares on the open market six times over the past year, totaling about $6.4 million. Her most recent sale occurred on January 21, 2026. These transactions rank her 1617th among 11,678 insiders by sale value, below the average of $8.6 million across 6.37 transactions per insider. She made no open market purchases in this period.
| Transaction Date | Company | Ticker | Insider Name | Title | Transaction Type | Security | Shares | Price | Shares Owned Following | Total Shares Outstanding | % of Owned | % of Outstanding |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Feb. 27, 2026 | Atrium Therapeutics, Inc. | $RNA | Boyce Sarah | Not found | A | Stock Option (Right to Buy) | 20000 | $0.00 | 20,000.0000 | 0 | 9999.99% | 0.00% |
| Feb. 27, 2026 | Avidity Biosciences, Inc. | $RNAM | Boyce Sarah | President and CEO | D | Stock Option (Right to Buy) | 400000 | $0.00 | 0.0000 | 150,675,742 | 100.00% | 0.27% |
| Feb. 27, 2026 | Avidity Biosciences, Inc. | $RNAM | Boyce Sarah | President and CEO | D | Stock Option (Right to Buy) | 165000 | $0.00 | 0.0000 | 150,675,742 | 100.00% | 0.11% |
| Feb. 27, 2026 | Avidity Biosciences, Inc. | $RNAM | Boyce Sarah | President and CEO | D | Stock Option (Right to Buy) | 300000 | $0.00 | 0.0000 | 150,675,742 | 100.00% | 0.20% |
| Feb. 27, 2026 | Avidity Biosciences, Inc. | $RNAM | Boyce Sarah | President and CEO | D | Stock Option (Right to Buy) | 200000 | $0.00 | 0.0000 | 150,675,742 | 100.00% | 0.13% |
| Feb. 27, 2026 | Avidity Biosciences, Inc. | $RNAM | Boyce Sarah | President and CEO | D | Common Stock | 474861 | $0.00 | 0.0000 | 150,675,742 | 100.00% | 0.32% |
| Feb. 27, 2026 | Avidity Biosciences, Inc. | $RNAM | Boyce Sarah | President and CEO | D | Stock Option (Right to Buy) | 386015 | $0.00 | 0.0000 | 150,675,742 | 100.00% | 0.26% |
| Feb. 27, 2026 | Avidity Biosciences, Inc. | $RNAM | Boyce Sarah | President and CEO | D | Stock Option (Right to Buy) | 300000 | $0.00 | 0.0000 | 150,675,742 | 100.00% | 0.20% |
| Feb. 27, 2026 | Avidity Biosciences, Inc. | $RNAM | Boyce Sarah | President and CEO | D | Stock Option (Right to Buy) | 425000 | $0.00 | 0.0000 | 150,675,742 | 100.00% | 0.28% |
| Jan. 21, 2026 | Avidity Biosciences, Inc. | $RNAM | Boyce Sarah | President and CEO | S | Common Stock | 6394 | $72.45 | 277,000.0000 | 150,675,742 | 2.26% | 0.00% |
| Jan. 21, 2026 | Avidity Biosciences, Inc. | $RNAM | Boyce Sarah | President and CEO | S | Common Stock | 7993 | $72.45 | 269,007.0000 | 150,675,742 | 2.89% | 0.01% |
| Jan. 7, 2026 | Avidity Biosciences, Inc. | $RNAM | Boyce Sarah | President and CEO | S | Common Stock | 8576 | $72.23 | 283,394.0000 | 150,675,742 | 2.94% | 0.01% |
| Dec. 17, 2025 | Avidity Biosciences, Inc. | $RNAM | Boyce Sarah | President and CEO | F | Common Stock | 15742 | $71.87 | 321,129.0000 | 150,675,742 | 4.67% | 0.01% |
| Dec. 17, 2025 | Avidity Biosciences, Inc. | $RNAM | Boyce Sarah | President and CEO | A | Common Stock | 31000 | $0.00 | 336,871.0000 | 150,675,742 | 10.13% | 0.02% |
| Dec. 18, 2025 | Avidity Biosciences, Inc. | $RNAM | Boyce Sarah | President and CEO | G | Common Stock | 29159 | $0.00 | 291,970.0000 | 150,675,742 | 9.08% | 0.02% |
| Sept. 5, 2025 | Avidity Biosciences, Inc. | $RNAM | Boyce Sarah | President and CEO | M | Common Stock | 50000 | $1.24 | 355,871.0000 | 120,212,301 | 16.35% | 0.04% |
| Sept. 5, 2025 | Avidity Biosciences, Inc. | $RNAM | Boyce Sarah | President and CEO | M | Stock Option (Right to Buy) | 50000 | $0.00 | 1,022,015.0000 | 120,212,301 | 4.66% | 0.04% |
| Sept. 5, 2025 | Avidity Biosciences, Inc. | $RNAM | Boyce Sarah | President and CEO | S | Common Stock | 50000 | $49.95 | 305,871.0000 | 120,212,301 | 14.05% | 0.04% |
| Aug. 28, 2025 | Avidity Biosciences, Inc. | $RNAM | Boyce Sarah | President and CEO | M | Stock Option (Right to Buy) | 25000 | $0.00 | 1,072,015.0000 | 120,212,301 | 2.28% | 0.02% |
| Aug. 28, 2025 | Avidity Biosciences, Inc. | $RNAM | Boyce Sarah | President and CEO | M | Common Stock | 25000 | $1.24 | 330,871.0000 | 120,212,301 | 8.17% | 0.02% |
| Aug. 28, 2025 | Avidity Biosciences, Inc. | $RNAM | Boyce Sarah | President and CEO | S | Common Stock | 25000 | $49.39 | 305,871.0000 | 120,212,301 | 7.56% | 0.02% |
| June 26, 2025 | Contineum Therapeutics, Inc. | $CTNM | Boyce Sarah | Director | A | Stock Option (right to buy) | 14750 | $0.00 | 14,750.0000 | 19,352,859 | 9999.99% | 0.08% |
| March 20, 2025 | Avidity Biosciences, Inc. | $RNAM | Boyce Sarah | President and CEO | S | Common Stock | 31540 | $31.06 | 305,871.0000 | 120,212,301 | 9.35% | 0.03% |
| Jan. 21, 2025 | Avidity Biosciences, Inc. | $RNAM | Boyce Sarah | President and CEO | S | Common Stock | 5659 | $28.59 | 337,411.0000 | 0 | 1.65% | 0.00% |
| Jan. 21, 2025 | Avidity Biosciences, Inc. | $RNAM | Boyce Sarah | President and CEO | S | Common Stock | 4738 | $28.59 | 343,070.0000 | 0 | 1.36% | 0.00% |
| Jan. 6, 2025 | Avidity Biosciences, Inc. | $RNAM | Boyce Sarah | President and CEO | A | Stock Option (Right to Buy) | 165000 | $0.00 | 165,000.0000 | 0 | 9999.99% | 0.00% |
| Jan. 6, 2025 | Avidity Biosciences, Inc. | $RNAM | Boyce Sarah | President and CEO | A | Common Stock | 82500 | $0.00 | 347,808.0000 | 0 | 31.10% | 0.00% |
| Dec. 18, 2024 | Avidity Biosciences, Inc. | $RNAM | Boyce Sarah | President and CEO | S | Common Stock | 31855 | $32.66 | 265,308.0000 | 0 | 10.72% | 0.00% |
| Sept. 19, 2024 | Avidity Biosciences, Inc. | $RNAM | Boyce Sarah | President and CEO | A | Common Stock | 62500 | $0.00 | 267,543.0000 | 0 | 30.48% | 0.00% |
| Sept. 19, 2024 | Avidity Biosciences, Inc. | $RNAM | Boyce Sarah | President and CEO | A | Common Stock | 62500 | $0.00 | 297,163.0000 | 0 | 26.63% | 0.00% |
| Sept. 23, 2024 | Avidity Biosciences, Inc. | $RNAM | Boyce Sarah | President and CEO | S | Common Stock | 32880 | $44.00 | 234,663.0000 | 0 | 12.29% | 0.00% |
| Aug. 6, 2024 | Avidity Biosciences, Inc. | $RNAM | Boyce Sarah | President and CEO | M | Stock Option (Right to Buy) | 28000 | $0.00 | 461,015.0000 | 0 | 5.73% | 0.00% |
| Aug. 6, 2024 | Avidity Biosciences, Inc. | $RNAM | Boyce Sarah | President and CEO | S | Common Stock | 28000 | $43.35 | 205,043.0000 | 0 | 12.01% | 0.00% |
| Aug. 6, 2024 | Avidity Biosciences, Inc. | $RNAM | Boyce Sarah | President and CEO | M | Common Stock | 28000 | $1.24 | 233,043.0000 | 0 | 13.66% | 0.00% |
| July 9, 2024 | Avidity Biosciences, Inc. | $RNAM | Boyce Sarah | President and CEO | M | Stock Option (Right to Buy) | 28000 | $0.00 | 489,015.0000 | 0 | 5.42% | 0.00% |
| July 9, 2024 | Avidity Biosciences, Inc. | $RNAM | Boyce Sarah | President and CEO | S | Common Stock | 28000 | $39.93 | 205,043.0000 | 0 | 12.01% | 0.00% |
| July 9, 2024 | Avidity Biosciences, Inc. | $RNAM | Boyce Sarah | President and CEO | M | Common Stock | 28000 | $1.24 | 233,043.0000 | 0 | 13.66% | 0.00% |
| June 24, 2024 | Contineum Therapeutics, Inc. | $CTNM | Boyce Sarah | Director | A | Stock Option (right to buy) | 29500 | $0.00 | 29,500.0000 | 2,308,972 | 9999.99% | 1.28% |
| June 18, 2024 | OmniAb, Inc. | $OABI | Boyce Sarah | Director | A | Restricted Stock Units | 20000 | $0.00 | 20,000.0000 | 0 | 9999.99% | 0.00% |
| June 18, 2024 | OmniAb, Inc. | $OABI | Boyce Sarah | Director | M | Restricted Stock Units | 20000 | $0.00 | 0.0000 | 0 | 100.00% | 0.00% |
| June 18, 2024 | OmniAb, Inc. | $OABI | Boyce Sarah | Director | M | Common Stock | 20000 | $0.00 | 68,381.0000 | 0 | 41.34% | 0.00% |
| June 18, 2024 | OmniAb, Inc. | $OABI | Boyce Sarah | Director | A | Stock Option (right to buy) | 40000 | $0.00 | 40,000.0000 | 0 | 9999.99% | 0.00% |
| June 18, 2024 | Avidity Biosciences, Inc. | $RNAM | Boyce Sarah | President and CEO | S | Common Stock | 32074 | $39.13 | 142,543.0000 | 0 | 18.37% | 0.00% |
| June 17, 2024 | Avidity Biosciences, Inc. | $RNAM | Boyce Sarah | President and CEO | A | Common Stock | 62500 | $0.00 | 205,043.0000 | 0 | 43.85% | 0.00% |
| June 17, 2024 | Avidity Biosciences, Inc. | $RNAM | Boyce Sarah | President and CEO | A | Common Stock | 62500 | $0.00 | 174,617.0000 | 0 | 55.75% | 0.00% |
| June 13, 2024 | Avidity Biosciences, Inc. | $RNAM | Boyce Sarah | President and CEO | M | Common Stock | 164233 | $1.24 | 276,350.0000 | 0 | 146.48% | 0.00% |
| June 13, 2024 | Avidity Biosciences, Inc. | $RNAM | Boyce Sarah | President and CEO | M | Stock Option (Right to Buy) | 164233 | $0.00 | 552,782.0000 | 0 | 22.91% | 0.00% |
| June 12, 2024 | Avidity Biosciences, Inc. | $RNAM | Boyce Sarah | President and CEO | M | Stock Option (Right to Buy) | 100000 | $0.00 | 717,015.0000 | 0 | 12.24% | 0.00% |
| June 14, 2024 | Avidity Biosciences, Inc. | $RNAM | Boyce Sarah | President and CEO | S | Common Stock | 35767 | $40.08 | 112,117.0000 | 0 | 24.19% | 0.00% |
| June 14, 2024 | Avidity Biosciences, Inc. | $RNAM | Boyce Sarah | President and CEO | M | Common Stock | 35767 | $1.24 | 147,884.0000 | 0 | 31.90% | 0.00% |
| June 13, 2024 | Avidity Biosciences, Inc. | $RNAM | Boyce Sarah | President and CEO | S | Common Stock | 164233 | $40.08 | 112,117.0000 | 0 | 59.43% | 0.00% |
| June 14, 2024 | Avidity Biosciences, Inc. | $RNAM | Boyce Sarah | President and CEO | M | Stock Option (Right to Buy) | 35767 | $0.00 | 517,015.0000 | 0 | 6.47% | 0.00% |
| June 12, 2024 | Avidity Biosciences, Inc. | $RNAM | Boyce Sarah | President and CEO | S | Common Stock | 100000 | $35.73 | 112,117.0000 | 0 | 47.14% | 0.00% |
| June 12, 2024 | Avidity Biosciences, Inc. | $RNAM | Boyce Sarah | President and CEO | M | Common Stock | 100000 | $1.24 | 212,117.0000 | 0 | 89.19% | 0.00% |
| June 4, 2024 | Avidity Biosciences, Inc. | $RNAM | Boyce Sarah | President and CEO | M | Stock Option (Right to Buy) | 28000 | $0.00 | 817,015.0000 | 0 | 3.31% | 0.00% |
| June 4, 2024 | Avidity Biosciences, Inc. | $RNAM | Boyce Sarah | President and CEO | S | Common Stock | 28000 | $27.42 | 112,117.0000 | 0 | 19.98% | 0.00% |
| June 4, 2024 | Avidity Biosciences, Inc. | $RNAM | Boyce Sarah | President and CEO | M | Common Stock | 28000 | $1.24 | 140,117.0000 | 0 | 24.97% | 0.00% |
| May 7, 2024 | Avidity Biosciences, Inc. | $RNAM | Boyce Sarah | President and CEO | S | Common Stock | 28000 | $25.54 | 112,117.0000 | 0 | 19.98% | 0.00% |
| May 7, 2024 | Avidity Biosciences, Inc. | $RNAM | Boyce Sarah | President and CEO | M | Common Stock | 28000 | $1.24 | 140,117.0000 | 0 | 24.97% | 0.00% |
| May 7, 2024 | Avidity Biosciences, Inc. | $RNAM | Boyce Sarah | President and CEO | M | Stock Option (Right to Buy) | 28000 | $0.00 | 845,015.0000 | 0 | 3.21% | 0.00% |
| Nov. 1, 2022 | OmniAb, Inc. | $OABI | Boyce Sarah | Director | A | Common Stock | 39628 | $0.00 | 48,381.0000 | 0 | 452.74% | 0.00% |
| April 2, 2024 | Avidity Biosciences, Inc. | $RNAM | Boyce Sarah | President and CEO | M | Common Stock | 28000 | $1.24 | 140,117.0000 | 0 | 24.97% | 0.00% |
| April 2, 2024 | Avidity Biosciences, Inc. | $RNAM | Boyce Sarah | President and CEO | S | Common Stock | 28000 | $26.25 | 112,117.0000 | 0 | 19.98% | 0.00% |
| April 2, 2024 | Avidity Biosciences, Inc. | $RNAM | Boyce Sarah | President and CEO | M | Stock Option (Right to Buy) | 28000 | $0.00 | 873,015.0000 | 0 | 3.11% | 0.00% |
| March 12, 2024 | Avidity Biosciences, Inc. | $RNAM | Boyce Sarah | President and CEO | M | Stock Option (Right to Buy) | 28000 | $0.00 | 901,015.0000 | 0 | 3.01% | 0.00% |
| March 8, 2024 | Avidity Biosciences, Inc. | $RNAM | Boyce Sarah | President and CEO | M | Common Stock | 84000 | $1.24 | 196,117.0000 | 0 | 74.92% | 0.00% |
| March 8, 2024 | Avidity Biosciences, Inc. | $RNAM | Boyce Sarah | President and CEO | S | Common Stock | 84000 | $21.39 | 112,117.0000 | 0 | 42.83% | 0.00% |
| March 12, 2024 | Avidity Biosciences, Inc. | $RNAM | Boyce Sarah | President and CEO | M | Common Stock | 28000 | $1.24 | 140,117.0000 | 0 | 24.97% | 0.00% |
| March 12, 2024 | Avidity Biosciences, Inc. | $RNAM | Boyce Sarah | President and CEO | S | Common Stock | 28000 | $22.63 | 112,117.0000 | 0 | 19.98% | 0.00% |
| March 8, 2024 | Avidity Biosciences, Inc. | $RNAM | Boyce Sarah | President and CEO | M | Stock Option (Right to Buy) | 84000 | $0.00 | 929,015.0000 | 0 | 8.29% | 0.00% |
| March 1, 2024 | Avidity Biosciences, Inc. | $RNAM | Boyce Sarah | President and CEO | M | Common Stock | 84000 | $1.24 | 196,117.0000 | 0 | 74.92% | 0.00% |
| March 1, 2024 | Avidity Biosciences, Inc. | $RNAM | Boyce Sarah | President and CEO | M | Stock Option (Right to Buy) | 84000 | $0.00 | 1,013,015.0000 | 0 | 7.66% | 0.00% |
| March 1, 2024 | Avidity Biosciences, Inc. | $RNAM | Boyce Sarah | President and CEO | S | Common Stock | 84000 | $20.13 | 112,117.0000 | 0 | 42.83% | 0.00% |
| Jan. 20, 2024 | Avidity Biosciences, Inc. | $RNAM | Boyce Sarah | President and CEO | A | Common Stock | 62500 | $0.00 | 67,209.0000 | 0 | 1327.25% | 0.00% |
| Jan. 20, 2024 | Avidity Biosciences, Inc. | $RNAM | Boyce Sarah | President and CEO | A | Stock Option (Right to Buy) | 300000 | $0.00 | 300,000.0000 | 0 | 9999.99% | 0.00% |
| Jan. 22, 2024 | Avidity Biosciences, Inc. | $RNAM | Boyce Sarah | President and CEO | S | Common Stock | 5092 | $10.13 | 44,008.0000 | 0 | 10.37% | 0.00% |
| Sept. 11, 2023 | Avidity Biosciences, Inc. | $RNAM | Boyce Sarah | President and CEO | A | Stock Option (Right to Buy) | 200000 | $0.00 | 200,000.0000 | 0 | 9999.99% | 0.00% |
| Feb. 1, 2023 | Avidity Biosciences, Inc. | $RNAM | Boyce Sarah | President and CEO | M | Common Stock | 900 | $1.24 | 54,252.0000 | 0 | 1.69% | 0.00% |
| Feb. 1, 2023 | Avidity Biosciences, Inc. | $RNAM | Boyce Sarah | President and CEO | S | Common Stock | 900 | $24.27 | 53,352.0000 | 0 | 1.66% | 0.00% |
| Feb. 2, 2023 | Avidity Biosciences, Inc. | $RNAM | Boyce Sarah | President and CEO | M | Common Stock | 45879 | $1.24 | 99,231.0000 | 0 | 85.99% | 0.00% |
| Feb. 2, 2023 | Avidity Biosciences, Inc. | $RNAM | Boyce Sarah | President and CEO | S | Common Stock | 45879 | $24.36 | 53,352.0000 | 0 | 46.23% | 0.00% |
| Feb. 3, 2023 | Avidity Biosciences, Inc. | $RNAM | Boyce Sarah | President and CEO | S | Common Stock | 3221 | $24.26 | 53,352.0000 | 0 | 5.69% | 0.00% |
| Feb. 3, 2023 | Avidity Biosciences, Inc. | $RNAM | Boyce Sarah | President and CEO | M | Common Stock | 3221 | $1.24 | 56,573.0000 | 0 | 6.04% | 0.00% |
| Feb. 3, 2023 | Avidity Biosciences, Inc. | $RNAM | Boyce Sarah | President and CEO | M | Stock Option (Right to | 3221 | $0.00 | 1,097,015.0000 | 0 | 0.29% | 0.00% |
| Feb. 2, 2023 | Avidity Biosciences, Inc. | $RNAM | Boyce Sarah | President and CEO | M | Stock Option (Right to Buy) | 45879 | $0.00 | 1,100,236.0000 | 0 | 4.00% | 0.00% |
| Feb. 1, 2023 | Avidity Biosciences, Inc. | $RNAM | Boyce Sarah | President and CEO | M | Stock Option (Right to Buy) | 900 | $0.00 | 1,146,115.0000 | 0 | 0.08% | 0.00% |
| Jan. 20, 2023 | Avidity Biosciences, Inc. | $RNAM | Boyce Sarah | President and CEO | A | Stock Option (Right to Buy) | 400000 | $0.00 | 400,000.0000 | 0 | 9999.99% | 0.00% |
| Jan. 20, 2023 | Avidity Biosciences, Inc. | $RNAM | Boyce Sarah | President and CEO | A | Common Stock | 50000 | $0.00 | 53,352.0000 | 0 | 1491.65% | 0.00% |